Clinical Trial

SNC116 Therapy for Refractory Systemic Lupus Erythematosus

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus.
Trial Details
NCT Number NCT07748156
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Shanghai Simnova Biotechnology Co.,Ltd.
Conditions Systemic Lupus Erythematosus
Enrollment 28 participants
Start Date 2026-08
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05